



AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-10 (Cancelled).

11. (Previously Presented) A pharmaceutical composition comprising at least one compound of formula (C) or (D) and a pharmaceutically acceptable carrier which is useful in a medicine




wherein -X' is



m is 0 or 1;

Y' is



Q is CH or N;

K is S or O;

v is 0, 1, or 2;

R⁶ is CO₂H, CO₂Alkyl, CO₂Aryl, CO₂NH₂, CO₂Aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, NH₂, NHAkyl, N(Alkyl)Alkyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, or CF₃;

R⁷, independently from R⁶, is H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, or NO₂;

R⁸, independently from R⁶ and R⁷, is H, CH₃, CH₂CH₃, CF₃, F, Cl, Br, I, CN, NO₂, or R⁶;

R^{9a} is H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, or NH₂;

R^{9b}, independently from R^{9a}, is H, NO₂, CF₃, F, Cl, Br, I, CN, CH₃, OCH₃, SH, or NH₂;

R¹⁰ is CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, CH₂SO₃H, CH₂SO₂NH₂, CH₂PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, CH₂NH₂, CH₂NHalkyl, CH₂N(alkyl)alkyl', CH₂OCH₃, or CH₂SH;

R¹¹ is CO₂H, CO₂alkyl, CO₂aryl, CO₂NH₂, CO₂aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, OH, NH₂, NHalkyl, N(alkyl)alkyl', OCH₃, or SH;

s is 1;

t is 0, 1, or 2;

-W- is -(CH₂)_v, *cis*-CH=CH- or *trans*-CH=CH-, and v is 0,1,or 2;

in case that R⁶ is NH₂, R⁷ or R⁸ or R^{9a} must not be H; and

in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R⁶ must not be NH₂ or SH;

or the pharmaceutically acceptable salts, esters, or amides of the compounds of formula (C) or (D).

12. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (C).



13. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (D).

14. (Withdrawn – Previously Presented) A method of inhibiting the binding of P-selectin, L-selectin or E-selectin to sLe^x or sLe^a and tyrosinesulfate residues in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.


15. (Withdrawn – Previously Presented) A method of treating, diagnosing, or preventing inflammatory disorders in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.

16. (Withdrawn – Previously Presented) A method of treating Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases, psoriasis, atopic dermatitis, rheumatoid arthritis, reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, organ transplants, traumatic shock, multi-organ failure, or an autoimmune disease selected from multiple sclerosis, asthma, and inflammatory bowel disease in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.

17. (New) A chemical compound of the formula (C) or (D)




wherein -X' is



m is 0 or 1;

Y' is



Q is CH or N;

K is S or O;

v is 0, 1, or 2;

R⁶ is CO₂H, CO₂Alkyl, CO₂Aryl, CO₂NH₂, CO₂Aralkyl, SO₃H, SO₂NH₂, PO(OH)₂, 1-H-tetrazolyl, CHO, COCH₃, CH₂OH, NH₂, NHAkyl, N(Akyl)Akyl', OCH₃, CH₂OCH₃, SH, F, Cl, Br, I, CH₃, CH₂CH₃, CN, or CF₃;

R^7 , independently from R^6 , is H, CH_3 , CH_2CH_3 , CF_3 , F, Cl, Br, I, CN, or NO_2 ;

R^8 , independently from R^6 and R^7 , is H, CH_3 , CH_2CH_3 , CF_3 , F, Cl, Br, I, CN, NO_2 , or R^6 ;

R^{9a} is H, NO_2 , CF_3 , F, Cl, Br, I, CN, CH_3 , OCH_3 , SH, or NH_2 ;

R^{9b} , independently from R^{9a} , is H, NO_2 , CF_3 , F, Cl, Br, I, CN, CH_3 , OCH_3 , SH, or NH_2 ;

R^{10} is CO_2H , CO_2alkyl , CO_2aryl , CO_2NH_2 , $CO_2aralkyl$, CH_2SO_3H , $CH_2SO_2NH_2$, $CH_2PO(OH)_2$, 1-H-tetrazolyl, CHO, $COCH_3$, CH_2OH , CH_2NH_2 , $CH_2NHalkyl$, $CH_2N(alkyl)alkyl'$, CH_2OCH_3 , or CH_2SH ;

R^{11} is CO_2H , CO_2alkyl , CO_2aryl , CO_2NH_2 , $CO_2aralkyl$, SO_3H , SO_2NH_2 , $PO(OH)_2$, 1-H-tetrazolyl, CHO, $COCH_3$, OH, NH_2 , $NHalkyl$, $N(alkyl)alkyl'$, OCH_3 , or SH;

s is 1;

t is 0, 1, or 2;

-W- is $-(CH_2)_v$, *cis*-CH=CH- or *trans*-CH=CH-, and v is 0, 1, or 2;

in case that R^6 is NH_2 , R^7 or R^8 or R^{9a} must not be H; and

in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R^6 must not be NH_2 or SH;

or a pharmaceutically acceptable salt, ester, or amide of the above identified compound of formula (C) or (D).

18. (New) The chemical compound of claim 17, wherein the compound is of formula (C) and all variables, indices, symbols, and substituents are as defined in 17, or a pharmaceutically acceptable salt, ester, or amide of the above identified compound of formula (C).

19. (New) The chemical compound of claim 17, wherein the compound is of formula (D) and all variables, indices, symbols, and substituents are as defined in 17, or a pharmaceutically acceptable salt, ester, or amide of the above identified compound of formula (D).